Kornimate/medical-research-clean huggingface dataset:
relation of consummatory & anticipatory food reward to obesity

Conditions: Obesity

Summary: obesity is associated with increased risk for mortality, atherosclerotic cerebrovascular disease, coronary heart disease, colorectal cancer, hyperlipidemia, hypertension, gallbladder disease, and diabetes mellitus, resulting in over 111,000 deaths annually in the united states (calle et al., 1999; flegal et al., 2005). in the us, 65% of adults are overweight or obese (hedley et al., 2004). unfortunately, the treatment of choice for obesity (behavioral weight loss treatment) only results in a 10% reduction in body weight on average and most patients regain this weight within a few years (jeffery et al., 2000). further, most obesity prevention programs do not reduce risk for future weight gain (stice, shaw, \& marti, 2006). the limited success of treatment and prevention interventions may be due to an incomplete understanding of the processes that increase risk for obesity. recent data suggest that obese adults show abnormalities in reward from food intake and anticipated food intake relative to lean adults, but the precise nature of these abnormalities is unclear and it has not been established whether these abnormalities predate obesity onset or are a consequence. it is vital to elucidate risk factors for obesity onset to advance understanding of etiological processes and determine the content of prevention and treatment programs. the goals of this study are to (1) determine whether adolescents at high-risk for obesity, by virtue of having two obese parents, show abnormalities in reward from food intake (consummatory food reward) and anticipated reward from food intake (anticipatory food reward) compared to adolescents who are at low-risk for obesity, (2) determine whether abnormalities in consummatory and anticipatory food reward increase risk for weight gain and obesity onset, (3) examine moderators that may amplify the relations of consummatory and anticipatory food reward to unhealthy weight gain, and (4) examine changes in consummatory and anticipatory food reward in those participants who show obesity onset relative to those not showing obesity onset.


Eligibility criteria:
inclusion criteria: * between 14-17 years old * bmi between 25th and 75th percentile exclusion criteria: * contraindicators of functional magnetic resonance imaging (fmri): metal implants, braces, pregnancy * symptoms of major psychiatric disorders (substance use disorders, conduct disorder, attention deficit hyperactive disorder, major depression, bipolar disorder, panic disorder, agoraphobia, generalized anxiety disorder) binge eating * current use of pyschoactive drugs * serious medical conditions (diabetes, brain injury) * current smoking * relevant food allergies * current weight loss dieting

Keywords: fmri obesity adolescents
eyelash growth from application of bimatoprost in gel suspension to the base of the eyelashes

Conditions: Hypertrichosis

Summary: objective: to determine if lumigan (bimatoprost) causes increased lash length when used in gel suspension applied to the base of the eyelashes. methods: subjects recruited from the bascom palmer eye institute were screened and those who met inclusion criteria were enrolled. each participant received two vials of gel suspension, which contained bimatoprost and normal saline, respectively, each mixed 1:1 with gonaktm gel and labeled "right eye" and "left eye" according to randomization. the suspension was applied to the eyelashes every evening on the designated eye for 6 weeks. lash length was measured with a caliper at enrollment, at weekly intervals during the study and at 1 and 3 months after study completion. visual acuity, ocular symptoms, intraocular pressure and photographs were documented at these same intervals. results: the average eyelash growth in the lumigan group was 2.01mm (vs. control average of 1.13mm) which was a statistically significant difference (p=0.009). the average intraocular pressure decreased equally in both groups (2.14 mmhg). no change in visual acuity or iris discoloration was noted in any of the subjects. discussion: our data showed an increase in eyelash length with use of lumigan in gel suspension, suggesting that it may have eyelash lengthening properties.

study completed

Eligibility criteria:
inclusion criteria: * age greater than 20 and less than 90 and patients who have previously used and are comfortable with applying mascara. exclusion criteria: * history of glaucoma, uveitis, pregnancy, allergic reaction to prostaglandins or the gel suspension, alopecia, and previous usage of other eyelash growth enhancement.

Keywords: bimatoprost eyelash lengthening prostaglandin analogs cosmetics
comparison of el-ganzouri risk index and airway ultrasonographic evaluation in thyroid surgery

Conditions: Thyroid Surgery; Difficult Intubation

Summary: the primary purpose of this prospective observational study was to compare these tests used to predict difficult intubation in patients undergoing thyroid surgery. secondarily; by comparing these tests, we aim to find the test that best predicts difficult intubation and to determine the incidence of difficult intubation in patients who will undergo thyroid surgery.

patients' demographic information (age, gender, american society of anesthesiologists (asa) classification, stop-bang score(snoring, feeling tired, observed apnea, hypertension, obesity, age, neck circumference and gender), body mass index) and thyroid ultrasonographic measurement will be recorded. at the preoperative visit, patients will be evaluated for el-ganzouri risk index (egri) scores (mouth opening, thyromental distance, mallampati score, neck movement limitation, presence of prognathia, body weight and history of difficult intubation) and for airway ultrasonography (skin-epiglottis distance, skin-hyoid bone distance, skin-vocal cord distance, tongue thickness and tongue volume values). after this information is recorded, patients will be grouped as those expected difficult intubation and those who are not. after the patients are taken to the operating table and monitored, vascular access will be opened, standard anesthesia induction will be applied to the patients by the room specialist, and laryngoscopy and endotracheal intubation will be performed by the trained (\>2 years experienced) anesthesiologist. if intubation difficulty scale (ids) score will be greater than 5, patient will be considered difficult intubation.

Eligibility criteria:
inclusion criteria: * patients with asa scores 1-3 * patients between 18-65 age * patients who undergo thyroid surgery exclusion criteria: * patients who do not accept to participate the research * patients under age 18 and over age 65 * pregnant patients * patients who undergo surgery due to emergency medical conditions (such as hematoma, thyroid crisis or myxedema coma) * patients with airway malformations * patients with a high risk of aspiration

Keywords: thyroid surgery el-ganzouri risk index airway ultrasonography difficult intubation
a study of paclitaxel with gdc-0941 versus paclitaxel with placebo in participants with locally recurrent or metastatic breast cancer

Conditions: Breast Cancer

Summary: this multicenter, randomized, single-blind, placebo-controlled, two arm study will evaluate the efficacy and safety of paclitaxel with gdc-0941 versus paclitaxel with placebo in participants with locally recurrent or metastatic breast cancer.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed adenocarcinoma of the breast, with measurable or non-measurable locally recurrent or metastatic disease * human epidermal growth factor receptor 2 (her2)-negative and hormone receptor (hr) (estrogen receptor and/or progesterone receptor)-positive disease as defined by local guidelines * eastern cooperative oncology group (ecog) performance status of 0 or 1 * adequate hematologic and end organ function * women of childbearing potential must agree to remain abstinent or to use two adequate methods of contraception, including at least one method with a failure rate of less than (\<) 1 percent (%) per year, during the treatment period and for at least 30 days after the last dose of study treatment or 6 months after discontinuation of paclitaxel, whichever is longer exclusion criteria: * prior non-capecitabine chemotherapy for locally recurrent or metastatic disease * prior treatment with a phosphoinositide 3-kinase (pi3k) inhibitor for advanced or metastatic breast cancer * history of intolerance to a taxane-containing therapy * history of clinically significant cardiac or pulmonary dysfunction * history of malabsorption syndrome or other condition that would interfere with enteral absorption * clinically significant history of liver disease * active autoimmune disease or active inflammatory disease * immunocompromised status due to current known active infection with human immunodeficiency virus (hiv) or due to the use of immunosuppressive therapies for other conditions * need for current chronic corticosteroid therapy * pregnant, lactating, or breastfeeding women * current severe, uncontrolled systemic disease * known untreated or active central nervous system (cns) metastases
therapeutic oxygen for gastrointestinal atony (toga)

Conditions: Ileus; Ogilvie Syndrome; Small Bowel Obstruction

Summary: this study is a non invasive study to see if 100% oxygen therapy will help to resolve an intestinal obstruction.

toga involves the provision of a 6- hour treatment with 100% oxygen via non breather mask to hospitalized patients with ileus, small bowel obstruction and/or colonic pseudo-obstruction will be a useful supplemental therapy, decreasing the diameter of the intestinal lumen and enhancing resolution of ileus/pseudo-obstruction

Eligibility criteria:
inclusion criteria: * patient or health proxy has been adequately informed of risks and benefits and agrees to his/her participation in the study. * patient is a hospitalized inpatient diagnosed with ileus, bowel obstruction or colonic pseudo-obstruction \[clinician interpretation or small bowel diameter ≥3.5 cm, cecal diameter ≥ 9 cm, sigmoid colon diameter ≥ 6 cm\]. * patient is clinically and hemodynamically stable * patient does not require supplemental oxygen greater than 2 liters per minute via nasal cannula * patient does not have any respiratory contraindications to 100% oxygen * failure to respond to non-surgical/non-endoscopic therapy for at least 24 hours, therapy at discretion of treating physician \[to eliminate patients with trivial ileus not requiring advanced intervention\] exclusion criteria: * patient is not expected to survive in the short term. * patient is a pregnant or lactating woman. * patient presents with severe or unstable psychiatric disorders. * patient is participating in concomitant research studies that would interfere with this study. * patient is an alcohol or drug abuser. * respirator support required. * unable to tolerate 100% oxygen for respiratory reasons or any other reasons. * perforation of the viscus. * inability to obtain informed consent. * hypoxemia, as in room air oxygen saturation less than 90%.

Keywords: bowel ischemia bowel perforation
study examining the effect of renal impairment on safety, toleration and how the body processes an experimental drug

Conditions: Obesity

Summary: cp-945,598 is eliminated following extensive metabolism. for some drugs, decreased renal (kidney) function can affect their elimination from the body via metabolism. this study will therefore compare the pharmacokinetics (time course of drug concentrations in the body), safety and tolerability of cp-945,598 in patients with severe renal impairment and healthy control subjects.


Eligibility criteria:
inclusion criteria: * normal subjects: 1.healthy. 2.matched for age (± 5 yrs), weight (± 10 kg), and gender ratio (± 2 subjects per gender). * subjects with renal disease: 1. severe impairment (creatinine clearance \<30 ml/min) 2. stable renal disease:no change in the last 30 days. 3. stable dose of medication and/or treatment. 4. reasonably well-controlled type 1 and type 2 diabetics exclusion criteria: * all subjects: non-prescribed use of drugs of abuse/ recreational drugs; recent treatment with experimental drugs or herbal experiments; ekg and blood pressure parameters falling outside of protocol-specified limits; history of regular alcohol or tobacco use exceeding protocol-specified limits * normal subjects: medically important health conditions; recent use of prescription or non-prescription medications. * subjects with renal disease: subjects requiring dialysis; certain chronic medical conditions; patients who have received renal transplant; severe and/or poorly controlled diabetes; treatment with protocol-specified drugs that may alter the way the body absorbs or processes cp-945,598.
a prospective, non-interventional, observational study of presentation, treatment patterns and outcomes in atypical hemolytic uremic syndrome patients

Conditions: Atypical Hemolytic Uremic Syndrome(aHUS)

Summary: this is a china, non-interventional, observational study and will follow the good phar-macoepidemiology practices guidelines. this study will enrol paediatric and adult patients diagnosed with ahus who will be treated according to routine clinical practice defined by local institutional treatment guidelines/protocol. those ahus patients who will be treated with a supportive therapy, which does not contain eculizumab, will be monitored for up to 12 months since the ini-tial diagnosis. patients initiated on eculizumab treatment anytime between ahus diagno-sis until 12 months will be followed for additional 12 months, starting from the ecu initia-tion. patient disposition, characteristics, outcomes and safety will be described for all pa-tients enrolled into this study


Eligibility criteria:
inclusion criteria: participants are eligible to be included in the study. age 1. patients of any age, who are diagnosed as ahus by a professional physician (first epi-sode or relapse). type of patient and disease characteristics 2. evidence of tma, including thrombocytopenia, evidence of hemolysis, and kidney dys-function, based on the following laboratory findings, should be recorded within 1 week time frame: 1. platelet count \< 150 per microliter (μl), and 2. mechanic hemolytic anemia evident by ldh ≥ 1.5 × upper limit of normal (uln), and hemoglobin ≤ lower limit of normal (lln) for age and gender and 3. serum creatinine level ≥ uln in adults (≥18 years of age), or ≥ 97.5th percentile for age at screening in children (patients who require dialysis for acute kidney injury are also eligi-ble). 3. gender: male and/or female.. informed consent 4. willing and able to give written informed consent and comply with the study visit schedule as described in section 6.2.1. for patients \< 18 years of age, patient's legal guardian must be willing and able to give written informed consent and the patient must be willing to give written informed assent (if applicable as determined by the central. exclusion criteria: participants are excluded from the study if any of the following criteria apply: medical conditions 1. patients who were diagnosed with hus only due to shiga toxin-producing escherichia coli (stec). 2. patients who were diagnosed with ttp (adamts13 activity \<10%). other exclusions 3. unable to give written informed consent. 4. any medical or psychological condition that, in the opinion of the investigator, could increase the risk to the participant by participating in the study or confound the outcome of the study.
evaluate the efficacy, safety and pharmacokinetics of gsk1325760a in the treatment of pulmonary arterial hypertension

Conditions: Hypertension, Pulmonary

Summary: the primary objective of this study is to evaluate the effect of gsk1325760a on improvement in exercise capacity in subjects with pulmonary arterial hypertension (pah). the secondary objectives of this study are to evaluate administration of gsk1325760a on: * the safety and tolerability * improvement of pah * the steady-state plasma pharmacokinetics of gsk1325760a


Eligibility criteria:
inclusion criteria: * subjects must have a diagnosis of pulmonary arterial hypertension (pah) in clinical classification of pulmonary hypertension group1 * the mean right heart catheterization parameters measured from 6 months prior to the administration of the investigational drug must meet the criteria below: * mean pulmonary arterial pressure (mpap) of \>25 mmhg * pulmonary vascular resistance (pvr) of \>3 mmhg/l/min * mean pulmonary capillary wedge pressure or left ventricular end diastolic pressure of \<15 mmhg (if measurable) * the measured six minutes walk distance (6mwd) at screening visit is in the range of =\>150m and \<=450m

Keywords: ambrisentan pulmonary arterial hypertension 6mwd
study of the safety and tolerability of axa1665 in subjects with mild and moderate hepatic insufficiency

Conditions: Hepatic Insufficiency

Summary: this is a randomized, single blind study to determine whether axa1665, a composition of naturally occuring amino acids, is well tolerated in subjects with mild and moderate hepatic insufficiency. study will also examine how the food product may influence the biology in muscle which will be assessed using magnetic resonance imaging (mri) and other functional assessments such as strength, balance and cognition as part of a comprehensive physical/neurological exam. changes in blood biomarkers of inflammation will also be assessed.


Eligibility criteria:
inclusion criteria: * willing to participate in the study and provide written informed consent * male and female adults aged \> 18 years * child-pugh score ≤9 (i.e. child-pugh class a or b) * liver frailty index (lfi) of ≥3.6 * willing and able to engage in 30 minutes of walking/physical activity at least 3 days per week exclusion criteria: * hospitalization for any complication of cirrhosis or taking new medications intended to treat hepatic encephalopathy within 2 months prior to screening or any hospitalization for any cause/reason within 30 days prior to screening * prior history or presence of a transjugular intrahepatic portal systemic shunt (tips) * current or history of significant alcohol consumption * other poorly controlled medical condition \[e.g., renal disease with an estimated glomerular filtration rate (gfr) \<60 ml/min/1.73m2) * known sensitivity and/or history of clinically significant food intolerance/allergies to proteins (including whey, soy, casein, amino acids, etc.) * any extreme or unbalanced diet such as ketogenic, atkins, paleo, vegan, etc. * unable or unwilling to adhere to contraception requirements * any contraindications to a mri scan * any other condition that, in the opinion of the investigator, renders the subject at risk for compliance, compromises the well-being of the subject, or hinders study completion

Keywords: amino acids, food study
humax-cd20 i(ofatumumab) n follicular lymphoma (fl) patients refractory to rituximab

Conditions: Lymphoma, Follicular

Summary: a single-arm, international, multi-center trial of humax-cd20 (ofatumumab), a fully human monoclonal anti-cd20 antibody, in patients with follicular lymphoma who are refractory to rituximab as monotherapy or in combination with chemotherapy

patients in the study will be randomized into two dose groups. patients in each dose group will receive one infusion of 300 mg of humax-cd20 followed by 7 weekly infusions of either 500 or 1000 mg of humax-cd20. disease status will be assessed every 3 months until month 24.

Eligibility criteria:
inclusion criteria * patient with follicular lymphoma grade 1 - 2 * refractory to rituximab given as monotherapy or in combination with any chemotherapy or to rituximab given as maintenance treatment following r-chemo, defined as: * failure to achieve at least pr to rituximab given as monotherapy or in combination with any chemotherapy; or, * disease progression while on rituximab (either given as monotherapy or in combination with any chemotherapy or during rituximab maintenance treatment following r-chemo); or, * disease progression in responders within 6 months of the last dose of rituximab (either given as monotherapy or in combination with any chemotherapy or after rituximab maintenance treatment schedule following r-chemo) * tumor verified to be cd20+ positive from excisional lymph node biopsy * ct scan in screening phase (based on local evaluation) showing: * 2 or more clearly demarcated lesions with a largest diameter ≥ 1.5 cm, or * 1 clearly demarcated lesion with a largest diameter ≥ 2,0 cm * ecog performance status of 0, 1, or 2 * age ≥ 18 years * following receipt of verbal and written information about the study, the patient must provide signed informed consent before any study related activity is carried out exclusion criteria * previous autologous stem cell transplantation within 6 months * previous allogeneic stem cell transplantation * more than 1 previous radio immunotherapy regimen * received radio immunotherapy within 3 months * received any anti-cancer treatment within 4 weeks * received monoclonal antibodies, other than rituximab within 3 months * patients previously treated with anti-cd20 monoclonal antibodies, other than rituximab * life expectancy less than 6 months

Keywords: ofatumumab rituximab nhl cd20 refractory
modulation of abeta levels by gsk933776 in alzheimer's disease patient

Conditions: Alzheimer's Disease

Summary: modulation of beta-amyloid levels in csf and plasma by gsk933776 in patients with mild alzheimer's disease or mild cognitive impairment

this is a phase i, an open label, single dose and parallel group study to assess short term pharmacodynamics and safety of gsk933776. the effect on the beta amyloid levels will be assessed in early (mci) and mild alzheimer's disease (ad) patients after a single dose of gsk933776 by i.v. administration.

Eligibility criteria:
inclusion criteria: * probable mild alzheimer's disease (mmse 20-26) or mild cognitive impairment * increase in total tau or p-tau in csf * decrease in amyloid beta in csf * stable dose of cholinesterase inhibitors, memantine or selegine or no treatment * body weight less than 120 kg * willingness to comply with contraceptive methods if self or partner is of child-bearing potential exclusion criteria: * any other cause of dementia * other significant neurologic or psychiatric illness * hachinski ischemia score \>4 * more than 3 microbleeds on mri * type 2 diabetes not controlled by diet * risk of cerebrovascular disease, cerebral haemorrhage or stroke * history of systemic autoimmune disease * use of platelet anti-aggregates or anti-coagulants (aspirin up to 325 mg/day is allowable) * use of chronic corticosteroids * uncontrolled hypertension in spite of antihypertensive medications * renal or hepatic insufficiency or clinically significant anaemia * in nursing home care * contraindications to lumbar puncture or mri * prior participation in therapeutic studies only after adequate wash-out period

Keywords: csf sampling alzheimer's disease amyloid beta levels
genetics of periodontal diseases in chinese (taiwan)

Conditions: Periodontal Disease

Summary: a retrospective case control study to validate the association between interleukin-1 gene variations and adult chronic periodontal disease in chinese (taiwan).


Eligibility criteria:
inclusion criteria: * to be included in this study, an individual needs to be han chinese of 35 years of age or older at time of enrollment. exclusion criteria: * subjects who, at time of enrollment, were pregnant or breastfeeding, or needed antibiotic prophylaxis before periodontal treatment will be excluded from this study.